Executive Editor-in-Chief, Global Journal of Oncology

Yonglei Liu, PhD
Executive Editor-in-Chief
Director of Editorial Office
Global Journal of Oncology

Education
2008-2011, Ph.D., Shanghai Medical College, Fudan University, Shanghai, China
2001-2004, MS., Department of Pathophysiology, Shanxi Medical University, China

Work Experince
2015-2016, Postdoctoral Fellow, Department of Environment Health, University of Indiana, US.
2014-2016, Postdoctoral Fellow, Fudan University, Research Center of Linyi Hospital, Shandong, China.
2011-2013, Postdoctoral Fellow, Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, US.
2004-2008, Research Associate, Cancer Research Center, Shandong Tumor Hospital and Institute, China.
Selected Publication
  1. Yonglei Liu, Jingling Zhang, Xiangjun Sun, et al. Down-regulation of miR-29b in carcinoma associated fibroblasts promotes cell growth and metastasis of breast cancer. Oncotarget. 2017 Apr 17.
  2. Yonglei Liu, Conghui Yu, Yonggang Wu, et al. CD44+Fibroblasts increases breast cancer cell proliferation and drug resistance by activating Hedgehog pathway via IGF2.Journal of Cellular and Molecular Medicine. 2017-01. Accepted.
  3. Yonglei Liu, Jingling Zhang, Xiangjun Sun, et al. EMMPRIN Down-regulating miR-106a/b Modifies Breast Cancer Stem Cell Properties via Interaction with Fibroblasts through Targeting STAT3 and HIF-1α. Scientific Reports. 2016, 6:28329.
  4. Yonglei Liu, Yutong Wang, Xiangjun Sun, et al. miR-449a Promotes Liver Cancer Cell Apoptosis by Down-regulation of Calpain6 and POU2F1. Oncotarget. 2016; 7(2): 13491-13501.
  5. Xiangjun Sun, Yonglei Liu*(corresponding author), Ming Li, et al. Involvement of miR-485-5p in Hepatocellular Carcinoma ProgressionTargeting EMMPRIN. Biomedicine & Pharmacotherapy. 2015; 72(5): 58-65.